Navigation Links
HIV drugs, Abacavir and Didanosine increase the risk of heart attack
Date:2/7/2008

A study to assess the adverse effects of anti-retroviral drugs shows that two widely-used HIV drugs are associated with an increased risk of heart attack/the formation of blood clots in the heart. With the use of Didanosine, the risk of developing a heart attack increases by 49%, with Abacavir; the increased risk is 90%. The effect is most pronounced in patients with a high underlying cardiovascular risk. The research findings also show that the adverse effect is reversible, if patients discontinue use of these particular drugs.

The scientists who conducted the study recommend that patients on Abacavir or Didanosine should evaluate their underlying cardiovascular risk with their doctor and discuss whether any changes to their drug regime are warranted. The scientists strongly urge HIV patients not to stop taking Abacavir or Didanosine, before they have consulted their doctor.

Since the study began in 1999, D:A:D (the Data Collection of Adverse effects of Anti-HIV Drugs Study) has examined the side-effects of anti-retroviral drugs, including a possible increase in the risk of heart attack. Recent analysis has focused on a class of drugs, not previously examined, known as the nucleoside analogues, which inhibit the HIV virus by preventing it from multiplying. This class of drugs includes Stavudine, Zidovudine, Lamivudine, Abacavir and Didanosine. Only the last two drugs in the analysis were shown to have an adverse effect with respect to heart disease.

The side-effects associated with Didanosine and Abacavir are, naturally, most significant for HIV-infected patients who already have a high underlying cardiovascular risk. The drug effect increases an individual persons underlying risk by a factor of 1.9 for a person on Abacavir, and 1.49 for a person on Didanosine. For a person with a low underlying risk, this increase in risk is still negligible, but for someone with a high underlying risk, this could have serious consequences. The study shows, however, that the risk of heart attack is removed once patients stop taking the drugs. This seems to be the case, regardless of how long these drugs have been used by patients.

The D:A:D study involves over 33,000 patients from Europe, Australia and Asia. The study evaluates the incidence of heart attack among HIV-infected patients undergoing anti-retroviral treatment, and thereby enables scientists to determine whether side-effects of the anti-retroviral drugs, including cardiovascular disease, are increased in the long-term.


'/>"/>

Contact: Communication Department
email@sund.ku.dk
453-532-7069
University of Copenhagen
Source:Eurekalert

Related medicine news :

1. Targeting gut bugs could revolutionize future drugs, say researcher
2. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
3. American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter
4. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
5. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
6. UKs largest charity announces increase in funding to almost £4 billion over 5 years
7. CRH Medical Corporation announces substantial increase in patient visits
8. Will This President Never Learn? Another Budget -- Another Increase to Ineffective Abstinence-Only Programs
9. FY2009 Budget Increases International Development Funding but Does Little for Domestic Nutrition Programs
10. ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32%
11. Natural Nutrition Operating Subsidiary Reports Record 29% Increase in Revenues for 2007 of $17,460,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... San Antonio, TX (PRWEB) , ... January 19, 2017 , ... ... Pate, has for the fifth consecutive year donated money to the Triumph Over Kid ... James A. Ragan was one of those children. James saw firsthand the effect of ...
(Date:1/19/2017)... ... 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to welcome ... Dr. Kim brings an extensive background in cutting-edge dermatology care and research to ... welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. ...
(Date:1/19/2017)... ... 19, 2017 , ... Each year, the Southeastern Society of ... hundreds of surgeons from over fifteen different countries come together to share and ... augmentation to breast reconstruction for breast cancer patients, teaching these surgical techniques ...
(Date:1/18/2017)... ... 18, 2017 , ... From a health perspective, 2017 will clearly be the ... to chronic disease, mental health and general physical well-being. The New York Times suggested ... consider. , For one Charlottesville restaurant, good gut health is clearly on the menu. ...
(Date:1/18/2017)... ... 2017 , ... The V Foundation for Cancer Research, a top-rated cancer research ... fundraising team, to compete in the Boston Marathon on April 17. From first-time ... oldest annual marathon to join Team V and support the Foundation’s mission to declare ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 18, 2017  Kratom leaves, from a South ... often used to prepare tea-like beverages and commercially ... Americans annually to increase alertness, enhance well-being and ... minor aches and pains. PinneyAssociates, review of the ... assist FDA and DEA in determining the most ...
(Date:1/18/2017)... Colo. , Jan. 18, 2017 Safe ... chain of pharmacies based in Loveland, Colorado ... Prescription Vials (LPVs) in selected Good Day locations.     ... have a cost-effective alternative for secure storage," said ... "For less than the price of a cup of ...
(Date:1/18/2017)... 2017 Invetech, the leading developer of ... therapies , has announced a collaboration agreement with ... starvation" treatments for acute leukemia and other oncology ... Invetech will develop systems to enable the commercial-scale ... technology platform, which uses a novel technology to ...
Breaking Medicine Technology: